Cargando…

Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC), often diagnosed at advanced stages without curative therapies, is the fifth most common malignant cancer and the second leading cause of cancer-related mortality. Polo-like kinase 1 (PLK1) is activated in the late G2 phase of the cell cycle and is required...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yan, Zhao, Zhen-Gang, Luo, Yin, Cui, Hao, Wang, Hao-Yu, Jia, Yan-Fang, Gao, Ying-Tang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Basic Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459198/ https://www.ncbi.nlm.nih.gov/pubmed/32921957 http://dx.doi.org/10.3748/wjg.v26.i32.4786

Ejemplares similares

Baculoviral IAP Repeat Containing 6 (BIRC6) Is a Predictor of Prognosis in Prostate Cancer
por: Zhuang, Wenzhen, et al.
Publicado: (2018)

TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma
por: Nikolova, Dafina, et al.
Publicado: (2018)

Baculoviral inhibitor of apoptosis protein repeat-containing protein 3 delays early Wallerian degeneration after sciatic nerve injury
por: Cai, Min, et al.
Publicado: (2021)

Paclitaxel Induce Apoptosis of Giant Cells Tumor of Bone via TP53INP1 Signaling
por: Xiao, Wei‐Yuan, et al.
Publicado: (2018)

Genetic rearrangements of variable di-residue (RVD)-containing repeat arrays in a baculoviral TALEN system
por: Lau, Cia-Hin, et al.
Publicado: (2014)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Baculoviral inhibitor of apoptosis family of proteins repeat-containing 5 gene methylation status in peripheral blood mononuclear cells and plasma survivin levels in patients with Behçet’s disease
por: PAHLAVAN, Yasamin, et al.
Publicado: (2021)

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells
por: Han, Ding-pei, et al.
Publicado: (2012)

Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells
por: Sydor, Svenja, et al.
Publicado: (2017)

Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway
por: Teng, Yong-Jie, et al.
Publicado: (2022)

Krüppel-like factor 5 promotes the progression of oral squamous cell carcinoma via the baculoviral IAP repeat containing 5 gene
por: Li, Yuehua, et al.
Publicado: (2022)

73565 Defining tp53 tumor suppressor functions in zebrafish embryonal rhabdomyosarcoma
por: Baxi, Kunal, et al.
Publicado: (2021)

P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA
por: Lam, Wing, et al.
Publicado: (2023)

Association Between a Polymorphism (rs2071214) in Baculoviral IAP Repeat Containing 5 Gene (BIRC5) and Ischemic Stroke in Korean Population
por: Chon, Jinmann, et al.
Publicado: (2016)

TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma
por: Yu, Jiongjie, et al.
Publicado: (2023)

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome
por: King, Sharon I, et al.
Publicado: (2012)

PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy
por: Ruf, Stefanie, et al.
Publicado: (2017)

Yinchenhao decoction attenuates obstructive jaundice-induced liver injury and hepatocyte apoptosis by suppressing protein kinase RNA-like endoplasmic reticulum kinase-induced pathway
por: Wu, Yan-Li, et al.
Publicado: (2019)

Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways
por: Huang, Qichao, et al.
Publicado: (2016)

Polo-Like Kinase 2: From Principle to Practice
por: Zhang, Chuanyong, et al.
Publicado: (2022)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma
por: Wu, Jing-Hua, et al.
Publicado: (2017)

A Novel Screening System for Claudin Binder Using Baculoviral Display
por: Kakutani, Hideki, et al.
Publicado: (2011)

TP53/MicroRNA Interplay in Hepatocellular Carcinoma
por: Pollutri, Daniela, et al.
Publicado: (2016)

Mouse Lung Fibroblast Resistance to Fas-Mediated Apoptosis Is Dependent on the Baculoviral Inhibitor of Apoptosis Protein 4 and the Cellular FLICE-Inhibitory Protein
por: Predescu, Sanda A., et al.
Publicado: (2017)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

SPOC domain-containing protein 1 regulates the proliferation and apoptosis of human spermatogonial stem cells through adenylate kinase 4
por: Zhou, Dai, et al.
Publicado: (2022)

Downregulation of Polo-Like Kinase 4 in Hepatocellular Carcinoma Associates with Poor Prognosis
por: Liu, Lili, et al.
Publicado: (2012)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma
por: Bussey, Kimberly J., et al.
Publicado: (2016)

Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2019)

The Association Between TP53 Arg72pro Polymorphism and Non-Melanoma Skin Cancer Risk: A Meta-Analysis Including 7,107 Subjects
por: Yang, Xueling, et al.
Publicado: (2013)

TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma
por: Shi, Yewen, et al.
Publicado: (2023)

The impact of TP53 activation and apoptosis in primary hereditary microcephaly
por: Iegiani, Giorgia, et al.
Publicado: (2023)

Drosophila Polo Kinase Is Required for Cytokinesis
por: Carmena, Mar, et al.
Publicado: (1998)

Polo kinase: the choreographer of the mitotic stage?
Publicado: (1996)

Regulation of the polo kinase during cytokinesis
por: Kachaner, David
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g92keqhaen7an8jgalhqidvpau